AR127966A1 - Formulaciones tópicas de inhibidores de pi3k-delta - Google Patents
Formulaciones tópicas de inhibidores de pi3k-deltaInfo
- Publication number
- AR127966A1 AR127966A1 ARP220103435A ARP220103435A AR127966A1 AR 127966 A1 AR127966 A1 AR 127966A1 AR P220103435 A ARP220103435 A AR P220103435A AR P220103435 A ARP220103435 A AR P220103435A AR 127966 A1 AR127966 A1 AR 127966A1
- Authority
- AR
- Argentina
- Prior art keywords
- pi3k
- topical formulations
- delta inhibitors
- skin
- pharmaceutically acceptable
- Prior art date
Links
- 229940124780 PI3K delta inhibitor Drugs 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- ZQPDJCIXJHUERQ-QWRGUYRKSA-N (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical group CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-QWRGUYRKSA-N 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Abstract
Reivindicación 1: Una composición farmacéutica, adecuada para la aplicación tópica en la piel de un paciente humano con un trastorno de la piel, caracterizada porque comprende: (1) una cantidad terapéuticamente eficaz de un agente terapéutico que es (R)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona, o una sal farmacéuticamente aceptable de este; y (2) un medio para efectuar la penetración en la piel del agente terapéutico o una sal farmacéuticamente aceptable de este para el paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163290518P | 2021-12-16 | 2021-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127966A1 true AR127966A1 (es) | 2024-03-13 |
Family
ID=85172615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103435A AR127966A1 (es) | 2021-12-16 | 2022-12-15 | Formulaciones tópicas de inhibidores de pi3k-delta |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230190755A1 (es) |
AR (1) | AR127966A1 (es) |
TW (1) | TW202329976A (es) |
WO (1) | WO2023114369A2 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물 |
KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
MX2020004398A (es) | 2014-04-08 | 2022-06-06 | Incyte Corp | Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k). |
MD20160137A2 (ro) * | 2014-05-27 | 2017-05-31 | Almirall S.A. | Utilizare medicală |
PE20180129A1 (es) * | 2015-02-27 | 2018-01-18 | Incyte Corp | Sales de inhibidor de pi3k y procesos de preparacion |
BR112020024427A2 (pt) | 2018-06-01 | 2021-03-23 | Incyte Corporation | regime de dosagem para o tratamento de distúrbios relacionados a pi3k |
-
2022
- 2022-12-15 WO PCT/US2022/052966 patent/WO2023114369A2/en unknown
- 2022-12-15 AR ARP220103435A patent/AR127966A1/es unknown
- 2022-12-15 US US18/081,975 patent/US20230190755A1/en active Pending
- 2022-12-15 TW TW111148338A patent/TW202329976A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20230190755A1 (en) | 2023-06-22 |
WO2023114369A2 (en) | 2023-06-22 |
WO2023114369A3 (en) | 2023-08-10 |
TW202329976A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
MX2021000376A (es) | Composiciones tópicas para el alivio del dolor. | |
AR002262A1 (es) | Composicion y metodo para el tratamiento de enfermedades fungales de las unas y un vendaje adaptado para la administracion topica de medicacion a lasunas. | |
MX2021004546A (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
BR0207024A (pt) | Medicamento com ação inicial rápida para o tratamento de disfunção sexual | |
AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
CL2009002183A1 (es) | Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
BR112015030578A2 (pt) | combinações farmacêuticas | |
CO5590913A2 (es) | Terapia de combinacion antivirica | |
HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
BRPI0807940B8 (pt) | usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido | |
WO2020170030A3 (en) | Method for providing early onset of action in the treatment of rosacea | |
AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
PT1220676E (pt) | Prevencao do cancro colorrectal | |
AR111699A1 (es) | Composición farmacéutica que comprende betahistina | |
EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
BRPI0416266A (pt) | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente | |
MX2021003030A (es) | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. | |
US11154542B2 (en) | Nail lacquer composition containing ciclopirox |